SG Americas Securities LLC Has $32.35 Million Holdings in Biogen Inc. $BIIB

SG Americas Securities LLC boosted its position in shares of Biogen Inc. (NASDAQ:BIIB) by 1,793.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 183,829 shares of the biotechnology company’s stock after buying an additional 174,122 shares during the period. SG Americas Securities LLC owned approximately 0.13% of Biogen worth $32,352,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Biogen by 1.0% in the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock valued at $938,007,000 after buying an additional 71,897 shares in the last quarter. Invesco Ltd. boosted its position in shares of Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares in the last quarter. Norges Bank bought a new position in Biogen in the second quarter valued at approximately $284,358,000. AQR Capital Management LLC raised its position in Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after purchasing an additional 418,776 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Biogen by 10.1% during the third quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock valued at $223,203,000 after purchasing an additional 146,583 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Stock Up 2.8%

Shares of BIIB opened at $189.18 on Thursday. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $202.41. The stock has a market capitalization of $27.76 billion, a price-to-earnings ratio of 21.47, a PEG ratio of 1.46 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a fifty day moving average of $184.53 and a 200-day moving average of $169.61.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the company posted $3.44 EPS. Biogen’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, sell-side analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on BIIB. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a report on Monday, February 9th. Morgan Stanley set a $190.00 price objective on Biogen in a research report on Sunday, February 8th. Oppenheimer raised their price objective on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. Tudor Pickering set a $201.00 target price on Biogen in a research report on Monday, February 9th. Finally, UBS Group initiated coverage on Biogen in a research note on Tuesday, January 6th. They set a “neutral” rating and a $185.00 target price for the company. Twelve analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $205.31.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.